SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10% Higher - Still a Buy?

Key Points

• SELLAS shares jumped 10% to $14.74 in midday trading, reaching as high as $14.90, despite trading volume falling 44% below the average session volume.
• Analyst sentiment remains mixed: two analysts rate the stock Buy while one rates it Sell, resulting in a consensus Hold rating and a $10 target price—well below the current share price.
• The company reported a quarterly loss of $0.05 per share, missing estimates by $0.01, while institutional investors increased their holdings and now own 17.38% of the stock.

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) shot up 10% during mid-day trading on Friday . The stock traded as high as $14.90 and last traded at $14.74. Approximately 4,624,310 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 8,185,436 shares. The stock had previously closed at $13.40.

Analyst Upgrades and Downgrades

SLS has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reissued a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Up 14.0%

The business's fifty day moving average is $11.69 and its 200-day moving average is $7.67. The company has a market cap of $3.09 billion, a PE ratio of -72.76 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently bought and sold shares of SLS. Nykredit A S bought a new stake in SELLAS Life Sciences Group during the second quarter valued at about $27,000. Wellington Management Group LLP lifted its position in shares of SELLAS Life Sciences Group by 73.2% during the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company's stock valued at $8,816,000 after buying an additional 252,531 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at approximately $7,823,000. Dagco Inc. grew its stake in shares of SELLAS Life Sciences Group by 19.8% during the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company's stock valued at $18,191,000 after acquiring an additional 203,653 shares during the period. Finally, Bank of America Corp DE increased its holdings in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company's stock worth $2,714,000 after acquiring an additional 540,748 shares in the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source